摘要
Graves眼病(GO)是一种以眶后淋巴细胞浸润为病理基础的自身免疫性疾病。其发病机制十分复杂,目前尚未得出准确的结论,但免疫因素在其中发挥了重要的作用。目前,还没有能够根除疾病的特异性药物。糖皮质激素是中重度、活动性GO患者的一线用药,但其副作用大,且存在不耐受的患者。因此免疫靶向药物作为一种新的治疗方案,展现出巨大的临床应用前景。随着GO发病机制的深入研究,近些年开展了许多免疫靶向药物的临床试验研究。本文重点介绍了利妥昔单抗(Rituximab,RTX)、替妥木单抗(Teprotumumab)和托珠单抗(Tocilizumab,TCZ)三种免疫靶向药物的研究进展,旨在为GO患者提供更多的治疗选择。值得注意的是,虽然这些免疫靶向药物有着独特的应用前景,但目前都因治疗效果不明确或成本问题在临床应用上受到限制。
Graves’ophthalmopathy(GO)is an autoimmune disease characterized by lymphocytic infiltration behind the eyes.The pathogenesis of this disease is complex,and although no definitive conclusion has been reached,immune factors are believed to play a significant role.Currently,no specific therapeutic drugs are available for GO.Glucocorticoids are recommended as first-line drugs for patients with moderate-to-severe,active GO,but they have significant side effects,and some patients are intolerant.Immune-targeted drugs offer a new treatment option with great promise for clinical application.Recent in-depth studies of the pathogenesis of GO have led to many clinical trial studies of immune-targeted drugs.This article highlights the research progress of three immune-targeted drugs,namely teprotumumab,rituximab(RTX),and tocilizumab(TCZ),with the aim of providing more therapeutic options for GO patients.It’s worth noting that although these immune-targeted drugs have unique application prospects,their clinical application is currently limited due to unclear therapeutic effects or cost issues.
作者
吕雯
付颖
Wen Lv;Ying Fu(Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China;Center for Endocrine Metabolism and Immune Diseases,Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China;Beijing Key Laboratory of Diabetes Research and Care,Beijing 101149,China)
